Literature DB >> 1419800

Monitoring of multiple myeloma and bone marrow fibrosis with aminoterminal propeptide of type III collagen (PIIINP).

T Taube1, K Franssila, L Risteli, J Risteli, I Elomaa.   

Abstract

Bone marrow fibrosis is known in myelomatosis and depends on the extent of plasma cell infiltration. The serum concentration of the aminoterminal propeptide of type III procollagen (PIIINP) has previously been reported to reflect fibrogenesis in the marrow in myelofibrosis. Here we followed 15 consecutive patients with newly diagnosed multiple myeloma with repeated PIIINP measurements during treatment with intermittent courses of melphalan and prednisolone. PIIINP was found to change with clinical behaviour of the disease, nonresponders and patients with recurrent disease having elevated values and the values in responders decreasing to the normal level or remaining there. Collagen fibres in plasma cell infiltrates of biopsies from bone marrow or skeletal tumours of these patients stained heavily with antibodies against PIIINP. Our results suggest that PIIINP works as a noninvasive indicator of bone marrow fibrogenesis. In multiple myeloma PIIINP is a sensitive, but not specific marker of disease course.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419800     DOI: 10.1111/j.1365-2141.1992.tb04590.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Type I collagen as a marker of bone metabolism in sickle cell hemoglobinopathies.

Authors:  D M Bolarin; P Swerdlow; A M Wallace; L Littsey
Journal:  J Natl Med Assoc       Date:  1998-01       Impact factor: 1.798

2.  TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia.

Authors:  Medhat Shehata; Josef D Schwarzmeier; Martin Hilgarth; Rainer Hubmann; Markus Duechler; Heinz Gisslinger
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

3.  Type I and type III collagen metabolites in adult osteosarcoma patients.

Authors:  T Wiklund; C Blomqvist; L Risteli; J Risteli; E Karaharju; I Elomaa
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

4.  Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.

Authors:  C Blomqvist; L Risteli; J Risteli; P Virkkunen; S Sarna; I Elomaa
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.